How can we advance health equity in 2022? Curebase founder and CEO, @tom_lemberg, says more #diversity and #patient#access in clinical trials.
Check out his full predictions in : https://t.co/M62qVpSart
We're excited to be partnering with @PersephoneBio and collaborating with @JanssenGlobal on a study to develop prevention strategies and better treatment options for colorectal cancer with a focus on participant #diversity and #access.
https://t.co/SVCpvNpMAH
This summer, we teamed up with @InBiosUSA to secure #EUA for the diagnostic company’s new COVID-19 IgG Antibody Rapid Test - one of many instances where our #DCT model has successfully supported #EUA for diagnostic tests during the pandemic.
https://t.co/gz9VB3ZgVm
We hope you were able to see Adam Samson, our Senior Director of ClinOps & Customer Success, present at #DTxEast2021 on long-term retention and monitoring in #patient outcomes in #DTx trials. Book a meeting with our team to learn more about #DCT in #DTx. https://t.co/gU9zrwLIym
Chatting on Clubhouse with the Gene Fixers @eperlste and Julia Vitarello Thursday at 2pm PT / 5pm ET.
Come see how decentralized trials and telemedicine intersect with rare disease.
https://t.co/L43cquh6qA
🗞️ @AdaptiveBiotech and @CurebaseDCT have announced a research collaboration to broaden patient participation in Adaptive's clinical studies. Their initial study will validate the effectiveness of Adaptive's #LymeDisease immune detection test.
PR: https://t.co/g4Rey7XMy1
Announcing our research collaboration with
@AdaptiveBiotech
! Brining DCTs to immune medicine.
First projects together:
- T-Detect™ for patients with Lyme disease
- COVID-19 long-term data study
#decentralized#clinicaltrials
https://t.co/A1LtR7UVL7
Bring your own Physician (BYOP) is our solution to bringing high-impact clinical trial options to every patient with their own doctors.
Thanks @DrugDiscoveryLR for covering Curebase.
https://t.co/auIv0ydc67